Abstract: Distinguishing between benign and malignant pancreatic cysts remains a clinical challenge. The aim of this study was to investigate the influence of body mass index (BMI) and preoperative clinical and cyst features, as described by the International Consensus Guidelines, on malignancy in patients with pancreatic mucinous cystic neoplasms (PMCNs).
INTRODUCTION

P
ancreatic cystic neoplasms (PCNs) are being diagnosed with increasing frequency due to the increased use of higher quality cross-sectional imaging and the aging of the population. 1 PCNs, which include serous cystic neoplasms (SCNs), mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), solid pseudopapillary neoplasms (SPNs), and various other cystic neoplasms, are a heterogeneous group of tumors with distinct biological features and a wide range of malignant potential, which depends on the histologic type. 2 Pancreatic mucinous cystic neoplasms (PMCNs), including IPMN and MCN, can trigger significant anxiety for patients and their physicians, as these cysts are considered to be premalignant lesions. 3, 4 Appropriately timed surgical resection can reduce the mortality from pancreatic cancer. However, surgical resection for PCN is associated with significant rates of morbidity and mortality. [5] [6] [7] Moreover, not all cysts have a similar risk of malignancy. Selecting patients with PCNs who should undergo surgical resection remains problematic in the absence of confirmed malignancy.
The 2012 International Consensus Guidelines for the management of PMCNs recommended surgical resection without further testing in patients whose cysts have suspected branch duct IPMN (BD-IPMN) with high-risk stigmata. 8 Cysts with worrisome features require further evaluation, and consideration of surgery is recommended in patients with such cysts because of the elevated risk of malignancy. 8 However, the guidelines for surgical resection of PMCNs cannot be applied to all PMCNs. 9 It is sometimes challenging to differentiate unifocal BD-IPMNs from MCNs on preoperative imaging studies. Many studies have used patient features and cystic features as the primary predictors for evaluating the malignant potential, with inconsistent results; as these predictors have been used to create consensus guidelines, the current guidelines may not be satisfactory. [10] [11] [12] [13] Further identification of additional factors and evaluating the additive role of multiple risk factors are required to preoperatively predict the malignant potential of PMCNs. Excess body weight is a risk factor for several types of human cancers, including colon, breast, esophageal, kidney, and pancreatic cancers. [14] [15] [16] [17] [18] Overweight and obesity are associated with the risk of pancreatic cancer, as well as worse overall survival. 15, 19, 20 A previous study has shown that, in Western countries, obesity is associated with a greater frequency of malignant transformation of BD-IPMNs. 21 The impact of body mass index (BMI) on the malignant progression of PMCNs has not previously been fully investigated in Asia. The purpose of this study was to determine whether overweight is associated with a greater frequency of malignant PMCNs in patients undergoing resection in Taiwan. The second aim of the study was to analyze the effect of the revised international guidelines by evaluating the influence of cystic features on the risk of malignancy in PMCNs.
METHODS
Patient Selection
The study population was drawn from patients undergoing surgery for PCNs between January 1994 and June 2014 at National Taiwan University Hospital. A total of 164 consecutive patients with pathologically proven PMCNs, including IPMNs and MCNs, formed the study group.
Data Collection
A retrospective review of clinical and pathologic information was performed. Information collected included age at the time of surgery, sex, smoking status, presence of symptoms (abdominal pain, jaundice, weight loss, and history of pancreatitis), presence of diabetes, anthropometric characteristics, preoperative carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) levels, imaging studies and pathology reports. BMI was calculated at the time of surgery. Radiographic variables analyzed included the type of imaging performed (computed tomography or magnetic resonance imaging), cyst size (recorded as the maximum dimension measured on cross-sectional imaging), and the presence of mural nodules, lymphadenopathy, and dilation of the pancreatic duct. Each case was retrospectively reviewed for high-risk stigmata and worrisome features, according to the revised International Consensus Guidelines. 8 Recorded high-risk stigmata included obstructive jaundice in a patient with a cystic lesion on the head of the pancreas, an enhancing solid component within the cyst, or the main pancreatic duct (MPD) that was larger than 10 mm in size. Recorded worrisome features included thickened/enhancing cyst walls, a main duct size of 5 to 9 mm, the presence of a non-enhancing mural nodule, and an abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy. In accordance with the revised guidelines, a cyst size of 3 cm or larger was not considered to be worrisome on its own; however, the predictive value of cyst size for malignancy was analyzed. The study was approved by the institutional review board of the National Taiwan University Hospital.
Interpretation of Pathological Diagnoses
All pathologic specimens were reviewed by a single experienced pathologist (Y.M. Jeng) to confirm the diagnosis of IPMN or MCN according to the World Health Organization (WHO) criteria. The degree of dysplasia was categorized as low-, intermediate-, or high-grade, according to the fourth edition of the WHO classification system. The IPMN were also classified into branch-duct IPMN (BD-IPMN), main-duct IPMN (MD-IPMN), or mixed IPMN; histological subtype classifications, ie, gastric, intestinal, pancreatobiliary, or oncocytic, were based on gross and microscopic histological findings. In this study, malignant IPMN and MCN were defined as invasive carcinomas. The PMCNs were classified as PMCNs (including all IPMNs and MCNs), PMCNs with the presence of a cyst on imaging (including all PMCNs except for MDIPMNs), IPMNs, and MCNs. Predictors of malignancy were investigated for each subgroup.
Statistical Analysis
To compare the between-group demographic data, we used Student unpaired t test for normally distributed continuous variables and the Mann-Whitney U test for non-normally distributed variables. We used the x 2 test for categorical data and Fisher exact test when cell counts were fewer than 5. Univariate analysis was performed to identify independent risk factors that were correlated with the presence of malignancy. We used multiple stepwise logistic regression analysis to identify significant independent risk factors that were correlated with the presence of malignancy in the univariate analysis. We also adjusted for age at study enrollment, sex, and biomedical characteristics to prevent confounding. We estimated the strength of the associations by calculating the odds ratio (OR). The optimal cutoff points for discriminating between malignant and benign tumors were sought by constructing receiver operating characteristic (ROC) curves, which were generated by calculating the sensitivities and specificities for BMI and CA 19-9 at several predetermined cutoff points. All tests were 2-tailed with the statistical significance level set at P < 0.05, and all analyses were performed with SPSS version 17.0 software (IBM, Armonk, New York, NY).
RESULTS
Patient Characteristics
A total of 164 patients with PMCNs, including 106 IPMNs and 58 MCNs, underwent surgical resection, and their complete records were reviewed. The patients' preoperative demographic and clinical characteristics are shown in Table 1 Table 2 shows a comparison of clinical features between the malignant and benign mucinous tumors. Patients with malignant mucinous tumors were older and more symptomatic than those with benign tumors. Of the 164 PMCNs, 42 (25.6%) tumors had high-risk stigmata, including 14 (45.2%) malignant tumors and 28 (21.1%) benign tumors (P ¼ 0.011). High-risk stigmata were more frequent in malignant tumors, including the presence of a main pancreatic duct that was >1 cm (38.7% vs. 19.5%, P ¼ 0.032), enhancing mural nodules (32.3% vs. 4.5%, P < 0.001) and obstructive jaundice (16.1% vs. 0.8%, P < 0.001). Of the 164 PMCNs, 98 (59.8%) tumors had worrisome features, including cysts >3 cm, wall thickness/enhancement, MPD 5 to 9 mm, and a non-enhancing mural nodule. Patients with malignant tumors were more likely to have an MPD that was >5 to 9 mm, abrupt dilatation of the MPD, and DM. Preoperative BMI was higher in patients with malignant PMCNs than in patients with benign PMCNs (25.6 AE 3.7 vs. 23.8 AE 2.9, P ¼ 0.004). The serum level of CA 19-9 was higher in patients with malignant tumors than in those with benign tumors (3287.6 AE 1771.5 vs. 70.1 AE 31.9, P ¼ 0.0001). The cyst size and serum CEA levels did not differ significantly between malignant and benign mucinous tumors.
Benign and Malignant PMCNs
Subgroup Analysis
Characteristics of Mucinous Tumors With Cysts on Imaging (All PMCNs Excluding Main-Duct IPMNs)
There were 132 mucinous tumors with cysts on imaging, including 66 BD-IPMNs, 8 mixed-type IPMNs, and 58 MCNs. We analyzed this subgroup because these patients are commonly encountered in clinical practice; however, it is not possible to confirm the diagnosis preoperatively, as these cystic lesions have similar imaging features. Table 2 displays a comparison of clinical features between the malignant and benign mucinous cystic tumors in this group. There were 23 malignant and 109 benign tumors. Patients with malignant cystic tumors were older and had more high-risk stigmata than patients with benign tumors, including the presence of enhancing mural nodules. The only worrisome feature that differed between patients with malignant versus benign tumors was the MPD between 5 and 9 mm, which was more common in patients with malignant tumors (21.7% vs. 2.8%, P ¼ 0.004). In patients with malignant tumors, DM was more common, and the preoperative BMI was higher. The proportion of patients who were overweight was higher among patients with malignant tumors than in patients with benign tumors (76.3% and 29.4%, respectively; P < 0.001). The serum level of CA 19-9 was higher in patients with malignant tumors. The cyst size, tumor location, number of cysts, history of acute pancreatitis, symptoms, smoking history, and serum CEA level did not differ significantly between patients with malignant tumors and those with benign tumors. ROC curve analysis showed that the optimal CA 19-9 cutoff for differentiating malignant tumors from benign tumors was 55.9 U/mL; the sensitivity was 61.9%, the specificity was 89.7%, and the area under the curve was 0.911 (95% CI: 0.704-0.917).
Characteristics of IPMNs and MCNs
Of the 106 IPMNs, there were 75 (70.8%) of the gastric subtype, 18 (17.0%) of the intestinal subtype, 12 of the (11.3%) pancreatobiliary subtype, and 1 (0.9%) of the oncocytic subtype. There were 26 malignant IPMCs. A comparison of the clinical features of malignant and benign IPMNs is shown in Table 3 . Malignant IPMNs had larger cysts and a higher rate of associated enhancing mural nodules, obstructive jaundice, an MPD between 5 and 9 mm and abrupt dilatation of the MPD. Patients with malignant IPMNs were more likely to have a BMI >25 and had higher serum CA 19-9 levels than patients with benign IPMNs. There were no statistically significant differences between malignant and benign IPMNs in terms of sex, age, tumor location, presence of symptoms, rates of DM, and serum CEA level.
Of the 58 MCNs, 5 were malignant and 53 were benign. Patients with malignant MCNs were older than those with benign MCNs (71.0 AE 6.0 vs. 45.8 AE 15.2 y, respectively; P ¼ 0.001). All 5 patients with malignant MCNs were symptomatic. Patients with malignant MCNs had higher BMI (28.6 AE 1.7 vs. 23.1 AE 2.7, P < 0.001) and higher serum CEA (143.4 AE 120.1 vs. 8.52 AE 7.27, P ¼ 0.003), and CA 19-9 levels (10253 AE 9189.9 vs. 30.0 AE 7.9, P ¼ 0.001) compared with patients with benign MCNs. Patients with malignant MCNs were more likely to have a BMI >25 (11/53 among patients with benign MCNs vs. 5/5 among patients with malignant MCNs, P ¼ 0.001). All 5 patients with malignant MCNs were overweight (BMI >25). There were no statistically significant differences in cyst size between malignant and benign MCNs.
Preoperative Predictors of Malignancy
Pancreatic Mucinous Cystic Neoplasms
In the univariate analysis, age, sex, presence of high-risk stigmata, DM, and BMI >25 were associated with a higher risk of malignancy (Table 4 ). In the multivariate analysis, only BMI >25 was an independent preoperative predictor for malignancy (OR 3.99, 95% CI: 1.59-10.004, P ¼ 0.003).
Mucinous Tumors With Cysts on Imaging
In the univariate analysis, age, sex, the presence of highrisk stigmata, a history of DM, CA 19-9 >37 U/mL, and a BMI >25 were associated with a higher risk of malignancy (Table 4) . In the multivariate analysis, both CA 19-9 >37 U/mL and BMI>25 were independent preoperative predictors for malignancy (OR 7.12, 95% CI: 2.11-24.03, P ¼ 0.002 and OR 5.33, 95% CI: 1.54 -18.42, P ¼ 0.008, respectively). 
Intraductal Papillary Mucinous Neoplasms
In the univariate analysis, CA 19-9 >37 U/mL and BMI >25 were associated with a higher risk of malignancy in patients with IPMNs. In the multivariate analysis, BMI >25 was an independent preoperative predictor of malignancy in IPMNs (OR 2.93, 95% CI: 1.03-8.31, P ¼ 0.043, respectively) ( Table 4) .
Mucinous Cystic Neoplasms
In the univariate analysis, CA 19-9 >37 U/mL and BMI >25 were associated with a higher risk of malignancy in MCNs (OR 19.56, 95% CI: 1.95-196.15, P ¼ 0.011 and OR 49, 95% CI: 4.37-549.25, P ¼ 0.002, respectively); however, these differences were not significant in the multivariate analysis (Table 4) . Table 5 shows the diagnostic value of predictors of malignancy according to the 2012 revised International Consensus Guidelines, BMI and CA 19-9 level. We combined mucinous tumors with cysts (BD-IPMN and MCN) for the analysis owing to their marked similarity on preoperative imaging studies. The presence of an enhancing mural nodule had the highest diagnostic accuracy (84.8%), with a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 17.4, 99.1, 80, and 85%, respectively. A combination of serum CA 19-9 level and BMI >25 increased the diagnostic accuracy for predicting malignancy from 72-78% to 84.1%. The combination of a BMI >25 and the presence of high-risk stigmata had the highest diagnostic accuracy (92.4%) for predicting malignancy.
Diagnostic Accuracy of Predictors of Malignancy
DISCUSSION
Selecting patients with PCN for surgical resection remains a major clinical challenge in the absence of confirmed malignancy. Preoperative evaluation of PCNs primarily relies on imaging findings; however, imaging alone has a high rate of misdiagnosis. 22 An improved understanding of the risk factors for cyst-related malignancy based on pre-operative cyst features and patient characteristics could assist in making management decisions. Previous studies have shown that older age, male sex, and the presence of diabetes are significant predictors of malignant cysts. 23 , 24 Sturm et al analyzed 274 patients with BD-IPMNs and demonstrated that obesity is associated with a greater frequency of malignancy among patients with BD-IPMN in Western countries. 21 Overweight and obesity are well-established risk factors for pancreatic adenocarcinoma and many other types of cancer. 17, 25 Pooled analyses and metaanalyses have confirmed an increased risk (20-50%) of pancreatic cancer in obese individuals. 26, 27 There are multiple mechanisms linking obesity to the promotion of gastrointestinal carcinogenesis, and increasing evidence suggests that obesity might also increase adenoma growth. [28] [29] [30] In the present study, the univariate analysis showed that older age, male sex, the The 2012 revised International Consensus Guidelines for the management of IPMNs suggested that these lesions should be resected in symptomatic patients, as well as those with high-risk stigmata or worrisome features. The frequency of malignancy of IPMN and MCN in our study was 24.5% and 8.6%, respectively, which are within the range reported in a prior surgical series. In our study, we confirmed that the cyst features described in the International Consensus Guidelines, including high-risk stigmata and some of the worrisome features, are associated with an increased risk of malignancy. Among the imaging findings in cases with high-risk stigmata and worrisome features, enhancing mural nodules had the highest accuracy for preoperatively predicting the malignancy of PMCNs, followed by MPD dilation and the presence of a non-enhancing mural nodule (Table 5) . Multiple cystic lesions were not significantly associated with malignancy. These findings are consistent with a recent meta-analysis that investigated the use of imaging findings to distinguish benign from malignant BD-IPMNs. 31 However, variables that have been found to be associated with malignancy in previous studies, as well as the indications for resection in the consensus guideline, were not significant in our multivariate analysis. When considering the clinical significance of each variable as a predictor of malignancy in the present study, only BMI >25 was found to be predictive of malignancy after multiple regression analysis. In particular, recent meta-analyses have yielded contradictory results regarding whether a cyst diameter of larger than 3 cm is a predictor of malignancy. 31, 32 In our study, cyst size was not significantly associated with risk of malignancy in PMCNs with cysts on imaging (combined IPMNs and MCNs) or in the analysis of the IPMNs and MCNs subgroups. Resection of PMCNs based on cyst size alone is therefore no longer appropriate.
CA 19-9 is an established tumor marker for pancreatic malignancy. The postoperative level of CA 19-9 has been reported to be useful in predicting survival after curative surgery for pancreatic adenocarcinoma. 33 One recent article reported that preoperative serum CA 19-9 could predict the presence of malignancy in pancreatic cystic neoplasm patients, with a 67% sensitivity and 78% specificity. 34 Increased CA 19-9 levels have been reported to be a predictor of malignancy in IPMNs. 35, 36 In our study, the preoperative CA 19-9 level could predict malignancy with 56.5% sensitivity, 82.6% specificity, and 78% accuracy in patients with PMCNs. In addition, serum CA 19-9 level combined with a BMI >25 increased the predictive accuracy to 84.1% in the present study, demonstrating that patient-related risk factors, such as CA 19-9, should be complementary factors that are taken into consideration with cystic features when deciding whether surgical intervention for PMCNs should be performed.
The retrospective nature of this study has some limitations. First, our analysis evaluated patients who underwent surgical resections, and thus there may have been selection bias between obese and non-obese patients. Second, we do not have complete data on lifestyle risk factors such as physical activity, which could confound our interpretation of the results. Third, the study was limited by its relatively small sample size for the analysis of each subgroup. Clearly, a large prospective cohort of PMCN patients, including multiple ethnic groups, should be studied over the long term to answer unsolved questions in the management of the increasing number of patients with PMCNs.
In summary, our data demonstrate that overweight is an independent preoperative predictor of malignancy in patients with IPMNs. As the prevalence of obesity continues to increase, the effects of obesity on the management of pancreatic cystic neoplasm must be elucidated and studied in the future. In addition, overweight is a modifiable risk factor, and weight control could prevent the progression of PMCNs to pancreatic cancer. More intensive surveillance or aggressive treatment may be required in overweight patients with PMCNs.
